CellOrigin announced treatment of the first patient with CAR-M in China and reported the second generation of CAR-M for solid tumors.

CellOrigin Biotechnology has announced the treatment of the first patient in China with their CAR-macrophage therapy product (CAR-M) SY001. This marks the first investigator-initiated clinical study of CAR-M cell therapy in China. The treatment was well tolerated with no dose-limiting toxicity observed, and the company expects that this innovative product will prove its safety and effectiveness in clinical trials, offering new hope for the treatment of solid tumors. CellOrigin has also collaborated with Zhejiang University on research papers exploring the development of second-generation CAR-iMAC and targeted glycan degradation for solid tumors. They are conducting further pre-clinical and clinical studies to provide safe and effective treatment choices for patients. [Extracted from the article]